This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
A trial looking at surgery for ovarian cancer that has come back (DESKTOP 3, ENGOT ov20) | Cancer Research UK
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Cytoreductive surgery before chemotherapy benefits women with recurrent ovarian cancer
PPT - An Oncology Exchange Activity PowerPoint Presentation, free download - ID:5600388
How to install ExaGear Desktop Trial on Odroid – ODROID
Clinical Development Program | RITUXAN HYCELA
Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA: #ASCO 2017 Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
Shannon Westin on X: "This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 #SGOatASCO #gyncsm https://t.co/pHGWklYWKs" / X
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
Study Design
AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4) - ppt video online download
A trial looking at surgery for ovarian cancer that has come back (DESKTOP 3, ENGOT ov20) | Cancer Research UK
GRIPHON Trial for Pulmonary Arterial Hypertension (PAH)
New Data Support Debulking to Prolong Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer
Destination Data: Activate Your Trial in 3 Simple Steps
ESGO on X: "👋 Ready for the next #ENYGO webinar? Register now for our webinar with Andreas du Bois. He'll talk about DESKTOP III Trial Results: Do patients in recurrent ovarian cancer
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
SENSCIS Trial | OFEV Clinical Study - SENSCIS | OFEV® (nintedanib) | OFEV
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial | Journal of Ovarian Research | Full Text
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
IJGC on X: "#podcast: The DESKTOP III Trial with Philipp Harter This week, @pedroramirezMD is joined by Prof. Philipp Harter to discuss The DESKTOP III Trial. ♫https://t.co/CZQXdMT97W @_kem @IGCSociety @ESGO_society @OncoAlert @agz_eriksson #
